By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) is honored to announce that Mr. Satter will be the keynote speaker at the Global Family Office BioForum Luncheon held as part of the LSN’s Redefining Early Stage Investments (RESI) Boston Partnering Event on September 18th at Park Plaza Hotel in Back Bay and will also be speaking on The Family Office panel in the afternoon.

Mr. Satter manages Satter Investment Management, a family office, and Alerce Investment Management, a private investment firm that invests in Life Science companies. He is a Director of Annexon Biosciences, an autoimmune and neurological diseases company. Additionally, he is currently involved in Alzheon, which is taking an orally administered plaque-preventing drug for treating Alzheimer’s disease through Phase II trials this year.

Mr. Satter was a partner at Goldman Sachs, where he spent 24 years, joining the merchant bank when it had $250 million of assets under management. When he retired, it had $130 Billion of assets under management. He was Global Head of the Mezzanine Group in the Merchant Banking Division, where he raised and managed over $30 billion of assets. He was a senior partner of the Investment Committee and the Chairman of the Risk Committee. As a former Goldman Sachs executive, Mr. Satter is the Vice Chairman of the board of the Goldman Sachs Foundation, and GS Gives, which is part of Goldman Sachs that runs the company’s charitable giving efforts. Mr. Satter is the Investment Committee’s Chairman, overseeing over $1 billion in assets.

He also runs the Satter Foundation, his family’s private foundation. As a philanthropist and global activist, Mr. Satter focuses on organizations he feels make the biggest difference to those who need it the most. Mr. Satter is a big supporter of the United States military and sits on the board and supports the Navy SEAL Foundation. He is also on the Board of Northwestern University.

After attending Northwestern University, he received a JD and MBA from Harvard Law School and Harvard Business School. He is married and has five daughters.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

With less than a month left until RESI Boston September 2023, LSN is very excited to announce the list of 50+ finalist companies who will be participating in the Innovator’s Pitch Challenge (IPC) at our next conference at the Boston Park Plaza on Monday, September 18, followed by 2 days of virtual partnering on September 19-20!

Over 50 companies representing therapeutics, medical devices, diagnostics, digital health, and R&D / life science tools across the globe will be delivering a live pitch followed by a Q&A session with a panel of investors and industry experts. In addition to the live pitching, all companies will be presenting a poster showcasing their technology in the exhibit hall. We look forward to featuring all of these high-caliber innovations at the upcoming RESI!

Below are the participating companies. If you are interested in seeing these pitches and engaging in one-on-one partnering with over 600 attendees expected to attend, you can register here!

We are also actively recruiting investors and industry experts to participate in our IPC sessions as judges reviewing the companies and asking them questions validating their company and technology. If interested, please reach out to research@lifesciencenation.com for more information.

RESI Boston September Pitch Companies

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

We are excited to announce an exclusive workshop that will be a pivotal highlight of the RESI Boston Conference, happening from September 18-20. Join us and unlock the door to non-dilutive grant funding for your early-stage health innovations

Workshop Topic: Leveraging NIH’s Non-Dilutive Grant Funding

Date: September 18th Time: 11:00 AM ET Location: Boston Park Plaza

Workshop Description

The NIH helps US-based small businesses in their early stages by offering over $1.3 billion in R&D funding through various programs. Small businesses can use NIH funding to generate proof-of-concept data, de-risk their innovation, and attract partners and investors to commercialize their innovation. We support a range of high-impact technologies, such as research tools, diagnostics, digital health, drugs, medical devices, and more. The NIH’s grants do not require equity and can provide the initial funding you need to translate your scientific innovations from an idea to a product. On this panel, representatives of the National Institute on Aging and the National Institute of General Medical Sciences will discuss how to apply for NIH funding, NIH-funded programs and entrepreneurial hubs which support founders across the nation, and unique priority areas in disease areas like Alzheimer’s disease and dementia.

Meet the Panelists

We are happy to introduce the speakers from the NIH who will provide a comprehensive overview of the relevant programs and their requirements:

Eddie Billingslea Small Business Strategy Coordinator National Institute on Aging	Joshua HOOKS Program Officer National Institute on Aging	Rajesh Kumar Program Officer National Institute on Aging

Get Registered for RESI Boston Conference

This workshop is an opportunity for attendees registered for the RESI Boston September conference. If you haven’t already, register now for RESI to gain access to this invaluable workshop and a multitude of other networking and learning opportunities.

Visit the NIA Exhibit Table

While at the conference, we encourage you to explore the NIA exhibit table. Engage with the experts directly, discover more about NIH Small Business Programs, and explore the vast potential for collaboration and innovation in aging-related research and development.

National Institute on Aging (NIA)

The National Institute on Aging’s (NIA) Small Business Programs manage the largest source of early-stage funding for aging-related R&D. With an annual budget of over $140 million, NIA provides R&D grants to small businesses through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Our mission is to develop interventions that prevent or treat Alzheimer’s disease (AD) and AD-related dementias, and we are committed to driving innovation in this critical field.

Join us at the RESI Boston Conference on September 18th at 11:00 AM ET and embark on a transformative journey into the world of non-dilutive grant funding, innovation, and collaboration. Register to meet NIA team and 300+ life science investors to unlock the potential of your health innovations.

Should you have any questions or require further information, please don’t hesitate to contact us at resi@lifesciencenation.com.

We look forward to welcoming you to this exciting event!

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

RESI Boston September will feature the Family Office BioForum, for both sourcing assets and identifying syndication partners bridging the gap between family offices and investment opportunities within the life sciences sector. The Family Office BioForum will feature an open-to-the-public Family Office Panel as part of the RESI program and an invitation-only luncheon discussing early-stage investment topics, including souring technology assets, identifying syndicate opportunities, and finding the right investment funds.

As the life sciences sector continues to burgeon with groundbreaking discoveries, therapies, and technologies, the need for early capital injection becomes ever more pronounced. The Family Office BioForum is a convergence point where family offices can simultaneously identify promising startups and collaborate with other like-minded investors.

The Power of Syndication

Syndication has emerged as a dynamic strategy in the investment landscape, offering distinct advantages to family offices and entrepreneurs seeking funding. Family offices can diversify risk and share due diligence efforts by joining forces with other investors in a syndicate. This collaborative approach allows investors to tap into a broader range of investment opportunities and capitalize on their combined expertise. Conversely, entrepreneurs benefit from access to a syndicate’s collective knowledge and resources, expediting fundraising and enhancing their chances of securing the necessary funds.

The Family Office Factor

Family offices are known for their long-term investment outlook and commitment to fostering meaningful impact. With a mission to preserve and grow their wealth across generations, family offices are uniquely positioned to contribute to the life sciences sector. Their involvement goes beyond monetary support; it encompasses mentorship, guidance, and a vested interest in the success of the ventures they invest in. The Global Family Office BioForum acknowledges this distinctive role and seeks to create an environment where family offices can connect with like-minded syndicate partners and explore transformative investment opportunities.

By Karen Deyo, Director of Product, Israel BD, LSN

Partnering for RESI Boston September, a hybrid event (in-person on September 18, or virtually on September 19-20) launches next Monday, giving registered attendees access to RESI’s unique partnering platform. This platform allows attendees to filter search results with a high degree of precision.

At RESI, unlike other conferences, requesting a meeting with an investor does not require a company to spend most of the initial meeting finding out if they are a fit for the investor or not. Companies can easily determine a list of investors who are interested in their sector, indication, and stage of development before requesting a meeting. Investor profiles are written by Life Science Nation (LSN)’s Investor Research team in a phone interview with each investor, as a requirement before registration.

The RESI Partnering Platform has an integrated video conferencing system, allowing companies to simply log in to the platform and initiate their meetings through their schedule. Make sure to look at the tutorial video below, to see all the features offered by our system!

Premier Platform Sample

Sign up for our free partnering tutorials below and register for RESI before partnering opens to have as much time as possible to maximize your partnering experience!

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Life Science Nation (LSN) is thrilled to be collaborating with the Government of Ontario and Ontario Bioscience Innovation Organization (OBIO) at the Redefining Early Stage Investments (RESI) conference, scheduled to take place from September 18-20 at the Boston Park Plaza. The first day will consist of in-person partnering, panels, pitches, and workshops, followed by two virtual partnering days. This collaboration brings together three influential organizations who are tackling the life sciences arena and aims to foster an ecosystem where innovation is nurtured and capital flows seamlessly in Ontario, Canada.

As part of this collaboration, the Government of Ontario and OBIO will be featuring a group of 15 early-stage startups to showcase the latest advancements across:

1. Nutrition
2. Polyphenols to treat chronic diseases
3. Robotic intramuscular injections
4. Wearable artificial kidney for ambulatory dialysis
5. Therapies and solutions in HDAC-driven pathologies, surgical oncology, complex inflammatory skin diseases, and onychomycosis
6. Electronic medical records
7. Non-viral and re-dosable gene therapies

These entrepreneurs will be provided with a unique platform to present their disruptive technologies, engage in one-on-one discussions with potential investors seeking to catalyze growth and expedite the journey toward impactful biotechnological breakthroughs.

With their unique and collaborative innovation ecosystem, Ontario is where companies come to grow and prosper. The same innovative spirit that led to the discovery of insulin in Ontario one hundred years ago has led to game-changing technologies such as 3D bioprinters and techniques to boost stem cell renewal. Whether you want to expand your operations here or source some of the highest quality medical products and services in the world, Ontario is your life sciences destination.

Get ready to meet the 15 startups and staff from Government of Ontario and OBIO at RESI Boston in September!

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

In the ever-evolving finance and investment landscape, family offices have emerged as key players with the potential to drive significant change. These private wealth management firms, entrusted with managing the financial affairs of affluent families, have diversified their portfolios to include investments in a wide array of sectors. One sector that has garnered substantial attention in recent years is healthcare. The intersection of wealth preservation, a family’s medical health profile, and social impact have led many family offices to focus on investing in healthcare, a decision that promises financial returns, improves family legacy, and impacts global well-being.

LSN Collaboration with Stetson Family Office in 2019

LSN launched the Global Family Office BioForum in 2019 in collaboration with the Stetson Family Office to match Family Offices with angel groups, early-stage VCs, and KOLs to help identify and vet early-stage healthcare investment opportunities.  This collaboration was an extension of Chuck Stetson’s visionary initiative on educating family offices to understand how they can impact chronic diseases like Alzheimer’s, Cancer, and Diabetes/Obesity and tackle big global healthcare issues through his Healthcare Impact Foundation. Over the years, the Global Family Office BioForum has witnessed many of these relationships fostered at LSN’s RESI partnering events grow into strategic alliances and investment syndicates that have helped Family Offices move into the early stage healthcare arena.

The Dynamics of Family Offices

Family offices, by their structure, cater to the unique financial needs of high-net-worth families. With a long-term perspective, they prioritize wealth preservation, growth, and the passing down of wealth to future generations. This approach aligns well with the characteristics of the healthcare sector, which, given its essential nature, presents a range of investment opportunities with the potential for both social impact and financial gains. New drug development can take a decade or more and cost hundreds of millions of dollars, while devices, diagnostics, and digital health technology can be developed in three to five years for five to 15 million.  This breadth of choice allows a family office to execute its financial, healthcare, and social impact goals.

Why Healthcare?

As I have stated in the past, planet Earth is in the golden age of life science. Like other investor classes, family offices want a high return rate based on a timeline that matches their money management goals.   The healthcare industry is undergoing rapid transformation, driven by technological advancements, changing demographics, and evolving consumer expectations. These shifts create fertile ground for investment, with opportunities that span pharmaceuticals, biotechnology, medical devices, telemedicine, healthcare IT, and more. The demand for innovative solutions to global health challenges is greater than ever, and family offices are positioning themselves as key contributors to this transformation.

Balancing Profit and Purpose

Family offices are uniquely positioned to balance profit with purpose. Investing in healthcare allows them to pursue financial returns and contribute to improving healthcare access, quality, and affordability. Many family offices see healthcare investments to align their financial goals with their desire to positively enhance their family legacy and society.

Driving Innovation

One of the remarkable aspects of family offices’ involvement in healthcare is their ability to drive innovation. By injecting capital into early-stage startups and research initiatives, family offices provide crucial support to ventures that may otherwise struggle to secure funding. This backing accelerates the development of groundbreaking therapies, technologies, and services, ultimately benefiting patients worldwide.